Fri, Sep 19, 2014, 11:00 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • larshansson18 larshansson18 Jun 19, 2012 10:00 AM Flag

    New report on Epicept. $$

    After todays news the Ceplene rights is fully in the hands of Epicept, but a geographical part (The EU and RIM-countries) and the production for these markets and the costs for the post approval study in the EU now is taken by Meda.

    Their is a more specified patientgroup for Ceplene after the latest results from Thorén et al (www.Pubmed.com)

    I wait for some initiatives from management concerning KOLs and the pathway forward for a new trial design in the US for Ceplene.

    No PP, but new deals seems to be next step. The Edison report is reasonable.

 
IMNP
3.46-0.06(-1.70%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
TC PipeLines, LP
NYSEFri, Sep 19, 2014 4:00 PM EDT